Ann Arbor, Michigan, US, and London, UK (PRWEB) April 13, 2011
NextGen Group plc (AIM:NGG) is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its plasmabreast25 multiplex protein assay, targeting breast cancer biomarker discovery and qualification. The assay simultaneously measures 25 human plasma proteins that are thought to have potential as biomarkers in breast cancer.
Klaus Rosenau, Chairman and CEO of NextGen Group, commented, ‘The release of plasmabreast25 is further indication of our commitment to developing and marketing multiplex assays for biomarker discovery in specific cancer areas. It enables us to remain focused on increasing our market share from the $600m mass spectrometry based biomarker discovery market. To ensure we continually deliver the high-quality assays that pharmaceutical, biotechnology and diagnostics companies need to inform their decision-making processes, NextGen Sciences is currently planning more such products in the near future.’
NextGen’s assay is based upon its multiple reaction monitoring (MRM) mass spectrometry platform and generates high quality reproducible data that companies can use in their drug and diagnostic development programmes. NextGen expects to develop further oncology and CNS disease-focused assay panels, both as proprietary products and with other companies, through partnerships and collaborations.
For more information please contact :
Klaus Rosenau, Chairman and CEO
+49 160 551 6756
Jonathan Wright, Nicola Marrin
+44 (0) 20 7107 8000
Notes to Editors
NextGen Sciences Inc (Ann Arbor, MI, USA) is the subsidiary of NextGen Group PLC, London, UK (AIM: NGG). It provides pharmaceutical, biotechnology and diagnostic companies with rapid and quantitative protein biomarker discovery, measurement and qualification services using mass spectrometry technology. With a rise in the industry focus on personalized medicine and cost-effectiveness, biomarkers are playing an increasingly important role in drug discovery, development and patient access, as well as healthcare delivery. The global market for biomarkers is expected to grow to $12.8bn by 2012 (BCC Research), with those for neurological disorders ($3.5bn by 2015, Espicom Healthcare) and oncology ($9.5bn by 2014, http://www.marketsandmarkets.com) playing an important role. NextGen Sciences’ products include discoveryexpress for discovery of new biomarkers and targets, assayexpress for assay development and testingexpress for biomarker qualification. For more information visit http://www.nextgensciences.com.